{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:25Z","timestamp":1784556985715,"version":"3.55.0"},"reference-count":30,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"\n Objective<\/jats:title>\n There is a scarcity of data from randomised controlled trials on the association of growth hormone (GH) with gonadotrophin-releasing hormone agonists in idiopathic short stature (ISS), although this off-label use is common. We aimed to test whether delaying pubertal progression could increase near-adult height (NAH) in GH-treated patients with ISS.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients with ISS at puberty onset were randomised to GH with leuprorelin (combination,\n n<\/jats:italic>\n \u2009=\u200946) or GH alone (\n n<\/jats:italic>\n \u2009=\u200945). NAH standard deviation score (SDS) was the primary outcome measure. The French regulatory authority requested premature discontinuation of study treatments after approximately 2.4 years; patients from France were followed for safety.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Mean (\n s.d.<\/jats:sc>\n ) baseline height SDS was \u22122.5 (0.5) in both groups, increasing at 2 years to \u22122.3 (0.6) with combination and \u22121.8 (0.7) with GH alone. NAH SDS was \u22121.8 (0.5) with combination (\n n<\/jats:italic>\n \u2009=\u200919) and \u22121.9 (0.8) with GH alone (\n n<\/jats:italic>\n \u2009=\u200916). Treatment-emergent adverse events and bone fractures occurred more frequently with combination than GH alone.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Due to premature discontinuation of treatments, statistical comparison of NAH SDS between the two cohorts was not possible. During the first 2\u20133 years of treatment, patients treated with the combination grew more slowly than those receiving GH alone. However, mean NAH SDS was similar in the two groups. No new GH-related safety concerns were revealed. A potentially deleterious effect of combined treatment on bone fracture incidence was identified.<\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/ec-18-0137","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T07:40:34Z","timestamp":1524037234000},"page":"708-718","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":14,"title":["Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature"],"prefix":"10.1530","volume":"7","author":[{"given":"Imane","family":"Benabbad","sequence":"first","affiliation":[{"name":"1Endocrinology and Diabetes Unit, Eli Lilly, Neuilly-sur-Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Rosilio","sequence":"additional","affiliation":[{"name":"1Endocrinology and Diabetes Unit, Eli Lilly, Neuilly-sur-Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mait\u00e9","family":"Tauber","sequence":"additional","affiliation":[{"name":"2Department Endocrine, Bone Diseases, Genetics, Obesity, and Gynecology Unit, Children\u2019s Hospital, University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Paris","sequence":"additional","affiliation":[{"name":"3BioClinica, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Paulsen","sequence":"additional","affiliation":[{"name":"4Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Universitaire Robert-Debr\u00e9, Department of Pediatric Endocrinology and Diabetology, and Centre de R\u00e9f\u00e9rence des Maladies Endocriniennes Rares de la Croissance, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovisa","family":"Berggren","sequence":"additional","affiliation":[{"name":"5Eli Lilly and Company, Bad Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiren","family":"Patel","sequence":"additional","affiliation":[{"name":"6Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Carel","sequence":"additional","affiliation":[{"name":"4Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Universitaire Robert-Debr\u00e9, Department of Pediatric Endocrinology and Diabetology, and Centre de R\u00e9f\u00e9rence des Maladies Endocriniennes Rares de la Croissance, Paris, France"},{"name":"4Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Universitaire Robert-Debr\u00e9, Department of Pediatric Endocrinology and Diabetology, and Centre de R\u00e9f\u00e9rence des Maladies Endocriniennes Rares de la Croissance, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"_","family":"_","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref211","first-page":"79","article-title":"GuaraldiFBeccutiGGoriDGhizzoniL Management of endocrine disease : long - term outcomes of the treatment of central precocious puberty of https org","journal-title":"European Journal Endocrinology"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jcem.84.10.6032","article-title":"Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study","volume":"84","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2007-1216","article-title":"Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpeds.2004.08.055","article-title":"Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect","volume":"146","year":"2005","journal-title":"Journal of Pediatrics"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1210\/jc.2011-1995","article-title":"Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1210\/jc.2015-2619","article-title":"Metabolic health in short children born small for gestational age treated with growth hormone and gonadotropin-releasing hormone analog: results of a randomized, dose-response trial","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref201","first-page":"247386","article-title":"Evaluating the efficacy of treatment with a GnRH analogue in patients with central precocious puberty","volume":"2015","year":"2015","journal-title":"International Journal of Endocrinology"},{"key":"ref241","first-page":"226","article-title":"Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue","volume":"254\u2013255","year":"2006","journal-title":"Molecular and Cellular Endocrinology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1210\/jc.2005-0891","article-title":"Effect of growth hormone dose on bone maturation and puberty in children with idiopathic short stature","volume":"91","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref21","first-page":"CD004440","article-title":"Recombinant growth hormone for idiopathic short stature in children and adolescents","volume":"3","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1687-9856-2014-15","article-title":"Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit","volume":"2014","year":"2014","journal-title":"International Journal of Pediatric Endocrinology"},{"key":"ref231","first-page":"651","article-title":"Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?","volume":"25","year":"2012","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000330157","article-title":"Review of growth hormone randomized controlled trials in children with idiopathic short stature","volume":"76","year":"2011","journal-title":"Hormone Research in Paediatrics"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa013555","article-title":"Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature","volume":"348","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1210\/jc.2004-2543","article-title":"Safety of growth hormone treatment in pediatric patients with idiopathic short stature","volume":"90","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"c7157","DOI":"10.1136\/bmj.c7157","article-title":"Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review","volume":"342","year":"2011","journal-title":"BMJ"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ghir.2015.08.006","article-title":"Attaining genetic height potential: analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years","volume":"25","year":"2015","journal-title":"Growth Hormone and IGF Research"},{"key":"ref101","first-page":"101","article-title":"Can we increase adolescent growth of https org","author":"CarelJC","journal-title":"European Journal Endocrinology"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2006-2272","article-title":"Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty","volume":"92","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jbmr.5650070204","article-title":"New approaches for interpreting projected bone densitometry data","volume":"7","year":"1992","journal-title":"Journal of Bone and Mineral Research"},{"key":"ref171","volume-title":"Radiographic Atlas of Skeletal Development of the Hand and Wrist","year":"1959"},{"key":"ref251","first-page":"744","article-title":"Use of GnRH agonists in GH-deficient patients: arguments for and against. The case for GnRH agonists in GH-deficient patients","volume":"5","year":"2008","journal-title":"Pediatric Endocrinology Reviews"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1210\/jc.2008-0509","article-title":"Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop","volume":"93","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3476(52)80205-7","article-title":"Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards","volume":"40","year":"1952","journal-title":"Journal of Pediatrics"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000098707","article-title":"Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature","volume":"68","year":"2007","journal-title":"Hormone Research"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000330159","article-title":"Safety of growth hormone treatment of children with idiopathic short stature: the US experience","volume":"76","year":"2011","journal-title":"Hormone Research in Paediatrics"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1210\/jc.2016-1317","article-title":"Puberty and pubertal growth in GH-treated SGA children: effects of 2 years of GnRHa versus no GnRHa","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000330150","article-title":"Treatment of idiopathic short stature: effects of gonadotropin-releasing hormone analogs, aromatase inhibitors and anabolic steroids","volume":"76","year":"2011","journal-title":"Hormone Research in Paediatrics"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1210\/jc.2007-0308","article-title":"Growth hormone treatment in adolescent males with idiopathic short stature: changes in body composition, protein, fat, and glucose metabolism","volume":"92","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref131","first-page":"221","article-title":"A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: previously published studies from America","volume":"254\u2013255","year":"2006","journal-title":"Molecular and Cellular Endocrinology"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/7\/5\/EC-18-0137.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/7\/5\/EC-18-0137.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:42:53Z","timestamp":1784554973000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/7\/5\/708-718\/333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":30,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/ec-18-0137","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}